FFAR1; FFAR4; DRD4; ADRA2C; ADRA2A; | |
TSHR; NPSR1; CXCR1; NMUR2; | |
PLA2G1B; TDP1; RECQL; CTDSP1; PKM; PIK3R1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B10; ALOX15; ALDH1A1; HSD17B2; ALOX12; AKR1B10; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; POLB; CD38; | |
PTPN1; | |
ACHE; GAA; | |
TRPA1; | |
CFTR; | |
PKN1; AKT1; MET; CAMK2B; CDK8; NEK6; CSNK2A1; DAPK1; SYK; FLT3; SRC; IGF1R; AURKB; AURKA; CDK9; GSK3B; KDR; CDK1; MAPK1; PIM1; NUAK1; ALK; PTK2; AXL; NEK2; CDK6; | |
CA12; CA7; CA3; CA14; CA5B; CA1; CA6; CA9; CA4; CA2; CA5A; | |
AR; | |
NR1H4; | |
NR1I2; | |
ESRRA; | |
PPARA; PPARG; PPARD; | |
ESR1; ESR2; | |
KDM4E; | |
MAOA; PTGS1; PTGS2; ALOX5; TYR; XDH; | |
PHF8; KDM7A; KDM2A; | |
MMP13; MMP12; MMP3; MMP2; MMP9; MMP1; | |
BACE1; | |
TLR2; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
ABCC1; ABCG2; | |
LMNA; FABP5; FABP2; FABP4; MAPT; FABP3; THPO; HTT; RAB9A; NPC1; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Metallo protease | MMP1 | Matrix metalloproteinase-1 | P03956 | CHEMBL332 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Nuclear hormone receptor subfamily 1 group C | PPARG | Peroxisome proliferator-activated receptor gamma | P37231 | CHEMBL235 |
Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 1 group I | NR1I2 | Pregnane X receptor | O75469 | CHEMBL3401 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Plant homeodomain | PHF8 | Histone lysine demethylase PHF8 | Q9UPP1 | CHEMBL1938212 |
Plant homeodomain | KDM7A | Lysine-specific demethylase 7 | Q6ZMT4 | CHEMBL2163177 |
Plant homeodomain | KDM2A | Lysine-specific demethylase 2A | Q9Y2K7 | CHEMBL1938210 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | CDK9 | Cyclin-dependent kinase 9 | P50750 | CHEMBL3116 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.815E-13 | 1.233E-10 | CYP1A2, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NR1I2 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 2.218E-12 | 4.978E-10 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, ALK, APP, CAMK2B, CD38, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, FLT3, HTT, IGF1R, KDR, L3MBTL1, MAPK1, MAPT, MET, MMP9, NFKB1, PARP1, PKM, PPARG, PTGS2, PYGL, RAB9A, SMN1, SMN2, STAT6, TP53, TRPA1, TTR, TYR, USP2, XDH |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.866E-12 | 7.942E-10 | AURKB, CA2, CA7, CFTR, HIF1A, HTT, MAPK1, NEK2, NPC1, NPSR1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.901E-11 | 3.566E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, NOX4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.953E-11 | 3.604E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.714E-11 | 1.093E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 1.003E-09 | 1.323E-07 | ABCC1, ABCG2, AKT1, ALK, AURKA, AURKB, AXL, CAMK2B, CDK1, CDK6, CDK8, CDK9, CFTR, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TP53 |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 1.114E-09 | 1.444E-07 | AR, CDK1, CDK8, CDK9, ESR1, ESR2, ESRRA, NR1H4, NR1I2, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.586E-09 | 1.951E-07 | AKT1, AURKA, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC, SYK, TNKS |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.148E-09 | 2.529E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.723E-09 | 9.132E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 9.469E-09 | 9.818E-07 | AHR, AKR1B1, AKT1, ALOX5, AR, AURKA, AURKB, CAMK2B, CDK1, CDK6, CDK8, CDK9, CSNK2A1, CTDSP1, ESR1, ESR2, ESRRA, FABP5, GSK3B, HIF1A, HTT, KDM2A, KDM7A, L3MBTL1, LMNA, MAPK1, NEK2, NEK6, NFKB1, NR1H4, NR1I2, NUAK1, PARP1, PHF8, PIM1, PKN1, POLB, PPARA, PPARD, PPARG, RECQL, SMN1, SMN2, SRC, STAT6, TNKS, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.188E-08 | 2.942E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 6.393E-08 | 5.438E-06 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1, TNKS |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 8.309E-08 | 6.816E-06 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 1.382E-07 | 1.078E-05 | AR, CYP3A4, ESR1, ESR2, ESRRA, HSD17B1, NPC1, NR1H4 |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 4.835E-07 | 3.385E-05 | ADRA2A, AKT1, AURKA, CDK9, ESR1, GSK3B, HIF1A, MAPK1, NEK6, PARP1, PIK3R1, PKN1, PTK2, PTPN1, SRC, SYK, TP53 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 6.989E-07 | 4.733E-05 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 6.999E-07 | 4.733E-05 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.219E-07 | 6.120E-05 | AURKA, AXL, CDK1, CSNK2A1, FLT3, PKM, PPARG |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 9.292E-07 | 6.150E-05 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC, SYK |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 1.019E-06 | 6.642E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 1.576E-06 | 9.694E-05 | ADRA2A, AKT1, FFAR1, HIF1A, NOX4, NR1H4, PIK3R1, PPARG, PYGL |
BP | GO:0008152; metabolic process | GO:0045944; positive regulation of transcription from RNA polymerase II promoter | 1.672E-06 | 1.019E-04 | AHR, AKT1, APP, AR, CDK8, CDK9, ESR1, ESRRA, HIF1A, MET, MMP12, NFKB1, NR1H4, NR1I2, PARP1, PIK3R1, PLA2G1B, PPARA, PPARG, STAT6, TLR2, TNKS, TP53 |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 2.140E-06 | 1.259E-04 | HIF1A, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 2.400E-06 | 1.401E-04 | ADRA2C, AKT1, ALOX12, APP, AR, AXL, CA2, CAMK2B, CDK1, CDK6, CTDSP1, CYP1B1, ESR1, ESRRA, GSK3B, HIF1A, KDR, L3MBTL1, MAPT, NR1H4, PIK3R1, PIM1, PPARD, PPARG, PTGS2, PTK2, SRC, STAT6, SYK, THPO, TLR2, XDH |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 2.489E-06 | 1.449E-04 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 3.159E-06 | 1.787E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 3.401E-06 | 1.919E-04 | AURKB, MAPK1, NEK2, TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 3.667E-06 | 2.047E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 3.667E-06 | 2.047E-04 | CDK1, CDK8, CDK9, MAPK1 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 4.769E-06 | 2.564E-04 | CYP2A6, CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0051179; localization | GO:0042307; positive regulation of protein import into nucleus | 5.146E-06 | 2.746E-04 | APP, CDK1, MAPK1, PARP1, PIK3R1, PTGS2, TLR2 |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 5.633E-06 | 2.999E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 6.287E-06 | 3.315E-04 | CYP1A1, CYP2C8, CYP3A4 |
MF | Unclassified; | GO:0004872; receptor activity | 6.317E-06 | 3.322E-04 | ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESR2, ESRRA, FFAR1, FFAR4, FLT3, IGF1R, KDR, MET, NMUR2, NPC1, NPSR1, NR1H4, NR1I2, PPARA, PPARD, PPARG, TLR2, TSHR |
CC | GO:0044464; cell part | GO:0005829; cytosol | 7.335E-06 | 3.805E-04 | AHR, AKR1B1, AKR1B10, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, APP, AR, AURKA, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, FABP2, FABP3, FABP4, FABP5, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, HTT, LMNA, MAPK1, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PPARG, PTK2, PTPN1, PYGL, RAB9A, SMN1, SMN2, SRC, STAT6, SYK, TNKS, TNKS2, TP53, TYR, XDH |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 7.636E-06 | 3.940E-04 | AKT1, HIF1A, LMNA, PPARD, PTGS2, SRC, TP53 |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 8.661E-06 | 4.407E-04 | ADRA2A, ADRA2C, AHR, AURKA, AXL, HIF1A, NFKB1, PIK3R1, PPARD, PPARG, TLR2, TP53, TTR, TYR |
MF | GO:0005488; binding | GO:0001223; transcription coactivator binding | 9.555E-06 | 4.827E-04 | AHR, CDK9, ESR1, PPARA |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.174E-05 | 5.823E-04 | CYP1A1, POLB, PPARG, TP53 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 1.408E-05 | 6.872E-04 | CA2, CA7, HTT, KDR, NPSR1, PARP1, PLA2G1B, SRC, TRPA1 |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 1.479E-05 | 7.190E-04 | CYP19A1, FFAR4, NFKB1, NR1H4, PPARA, PPARD, PPARG |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 1.745E-05 | 8.384E-04 | IGF1R, KDR, PTK2, SRC, SYK |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.752E-05 | 8.384E-04 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.743E-05 | 8.384E-04 | ADRA2A, ADRA2C, DRD4 |
BP | GO:0008152; metabolic process | GO:0031331; positive regulation of cellular catabolic process | 1.876E-05 | 8.902E-04 | ADRA2A, AKT1, AURKA, CDK1, DAPK1, GSK3B, HIF1A, HTT, KDR, PPARA, PTK2, PTPN1 |
BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.876E-05 | 8.902E-04 | ADRA2A, AKT1, APP, AURKA, CDK1, DAPK1, GSK3B, MAPT, PPARG, PTK2, SRC, XDH |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 2.023E-05 | 9.554E-04 | AKR1B1, AKT1, AR, CFTR, PPARG, SRC |
BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 2.068E-05 | 9.724E-04 | FLT3, HIF1A, KDR, L3MBTL1, MAPK1, PKN1, POLB, TYR |
BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 2.429E-05 | 1.113E-03 | FABP2, FABP3, FABP4, FABP5 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 2.601E-05 | 1.168E-03 | NR1H4, PLA2G1B, PYGL |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 2.773E-05 | 1.232E-03 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0032502; developmental process | GO:0007568; aging | 3.224E-05 | 1.415E-03 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, PTGS2, TP53 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 3.334E-05 | 1.446E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 3.334E-05 | 1.446E-03 | APP, GSK3B, IGF1R, PARP1 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 3.689E-05 | 1.563E-03 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 3.697E-05 | 1.563E-03 | CA2, CA7, CFTR |
BP | GO:0008152; metabolic process | GO:0070544; histone H3-K36 demethylation | 3.697E-05 | 1.563E-03 | KDM2A, KDM7A, PHF8 |
BP | GO:0008152; metabolic process | GO:0051974; negative regulation of telomerase activity | 3.697E-05 | 1.563E-03 | PPARG, SRC, TP53 |
BP | GO:0051179; localization | GO:0042908; xenobiotic transport | 3.697E-05 | 1.563E-03 | ABCC1, ABCG2, NR1I2 |
MF | GO:0003824; catalytic activity | GO:0051864; histone demethylase activity (H3-K36 specific) | 3.697E-05 | 1.563E-03 | KDM2A, KDM7A, PHF8 |
BP | GO:0008152; metabolic process | GO:0046320; regulation of fatty acid oxidation | 3.869E-05 | 1.605E-03 | AKT1, FABP3, PPARA, PPARG |
BP | GO:0008152; metabolic process | GO:0016572; histone phosphorylation | 3.869E-05 | 1.605E-03 | AURKA, AURKB, CDK1, PKN1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 3.869E-05 | 1.605E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | GO:0008152; metabolic process | GO:0035574; histone H4-K20 demethylation | 4.706E-05 | 1.884E-03 | KDM7A, PHF8 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 4.706E-05 | 1.884E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 4.706E-05 | 1.884E-03 | PTGS1, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 4.706E-05 | 1.884E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 4.706E-05 | 1.884E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0035575; histone demethylase activity (H4-K20 specific) | 4.706E-05 | 1.884E-03 | KDM7A, PHF8 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 5.007E-05 | 1.990E-03 | AKT1, HIF1A, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 5.057E-05 | 1.999E-03 | AR, CYP19A1, ESR1 |
MF | GO:0005488; binding | GO:0034452; dynactin binding | 5.057E-05 | 1.999E-03 | GSK3B, HTT, MAPT |
BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 5.332E-05 | 2.081E-03 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 5.851E-05 | 2.235E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
MF | GO:0005488; binding | GO:0030332; cyclin binding | 5.851E-05 | 2.235E-03 | CDK1, CDK6, CDK9, USP2 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 6.267E-05 | 2.386E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 6.289E-05 | 2.386E-03 | ADRA2A, CD38, PARP1, SRC, TNKS, TNKS2, TRPA1 |
BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 6.709E-05 | 2.519E-03 | ESR1, MAPK1, STAT6 |
BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 6.862E-05 | 2.552E-03 | APP, CFTR, NOX4, PPARG, PTGS2, TP53, TYR |
BP | GO:0032501; multicellular organismal process | GO:0051241; negative regulation of multicellular organismal process | 6.869E-05 | 2.552E-03 | ADRA2C, ALOX12, APP, AXL, CD38, CDK6, CTDSP1, FFAR4, GSK3B, HIF1A, LMNA, NFKB1, NR1H4, PIK3R1, PPARD, PPARG, PTGS2, PTK2, TLR2, XDH |
BP | Unclassified; | GO:0045907; positive regulation of vasoconstriction | 7.529E-05 | 2.774E-03 | ADRA2C, AKT1, CD38, PTGS2 |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 7.876E-05 | 2.877E-03 | CDK6, GSK3B, KDR, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 7.876E-05 | 2.877E-03 | AKT1, AR, DAPK1, HTT, LMNA, SRC |
CC | GO:0043226; organelle | GO:0044454; nuclear chromosome part | 7.955E-05 | 2.892E-03 | AR, AURKA, AURKB, CDK1, CSNK2A1, ESR1, NR1H4, PARP1, PPARD, STAT6, TNKS, TNKS2, TP53 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 8.487E-05 | 3.070E-03 | ADRA2A, ADRA2C, AKT1, SRC |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 8.678E-05 | 3.134E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 8.843E-05 | 3.181E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
MF | GO:0003824; catalytic activity | GO:0004693; cyclin-dependent protein serine/threonine kinase activity | 9.532E-05 | 3.413E-03 | CDK1, CDK6, CDK8, CDK9 |
BP | GO:0051179; localization | GO:0032368; regulation of lipid transport | 9.734E-05 | 3.469E-03 | AKT1, CYP19A1, NFKB1, PPARA, PPARG, SYK |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 1.057E-04 | 3.711E-03 | AKT1, HIF1A, NFKB1, PPARA, SRC |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 1.067E-04 | 3.718E-03 | CA2, CD38, SRC, SYK |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 1.099E-04 | 3.810E-03 | CYP19A1, ESR1, SRC |
MF | GO:0003824; catalytic activity | GO:0032454; histone demethylase activity (H3-K9 specific) | 1.099E-04 | 3.810E-03 | KDM4E, KDM7A, PHF8 |
MF | GO:0005488; binding | GO:0000977; RNA polymerase II regulatory region sequence-specific DNA binding | 1.130E-04 | 3.904E-03 | AHR, AR, CDK9, ESR1, ESR2, ESRRA, HIF1A, NFKB1, NR1H4, NR1I2, PARP1, PPARA, STAT6, TP53 |
MF | Unclassified; | GO:0032403; protein complex binding | 1.165E-04 | 4.007E-03 | ACHE, ADRA2A, FLT3, IGF1R, KDR, MMP12, MMP13, MMP9, PIK3R1, PKM, PPARA, PTPN1, SRC, SYK, TLR2, TSHR |
BP | GO:0009987; cellular process | GO:0045742; positive regulation of epidermal growth factor receptor signaling pathway | 1.190E-04 | 4.066E-03 | ADRA2A, ADRA2C, AKT1, MMP9 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 1.213E-04 | 4.128E-03 | GSK3B, HIF1A, HTT, NUAK1, TP53 |
MF | GO:0005488; binding | GO:0001046; core promoter sequence-specific DNA binding | 1.253E-04 | 4.241E-03 | CDK9, ESR1, ESR2, PPARG, STAT6, TP53 |
MF | GO:0140110; transcription regulator activity | GO:0001228; transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific DNA binding | 1.254E-04 | 4.241E-03 | AR, ESR1, ESRRA, HIF1A, NFKB1, NR1H4, NR1I2, PARP1, PPARA, STAT6, TP53 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.271E-04 | 4.280E-03 | ALOX5, CXCR1, FABP5, GAA, MAPK1, MMP9, MPO, NFKB1, PKM, PYGL, TLR2, TTR |
BP | GO:0065007; biological regulation | GO:0051101; regulation of DNA binding | 1.316E-04 | 4.411E-03 | MMP9, NEK2, PARP1, PPARA, PPARG, TNKS |
BP | GO:0022414; reproductive process | GO:0007566; embryo implantation | 1.322E-04 | 4.419E-03 | MMP2, MMP9, PPARD, PTGS2 |
BP | GO:0008152; metabolic process | GO:0033169; histone H3-K9 demethylation | 1.367E-04 | 4.548E-03 | KDM4E, KDM7A, PHF8 |
BP | GO:0065007; biological regulation | GO:0051099; positive regulation of binding | 1.368E-04 | 4.548E-03 | APP, CDK9, GSK3B, MET, MMP9, PARP1, PPARG |
BP | GO:0032501; multicellular organismal process | GO:0032481; positive regulation of type I interferon production | 1.387E-04 | 4.598E-03 | MMP12, NFKB1, STAT6, SYK, TLR2 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 1.387E-04 | 4.598E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0032501; multicellular organismal process | GO:0014005; microglia development | 1.405E-04 | 4.602E-03 | APP, TLR2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.405E-04 | 4.602E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.405E-04 | 4.602E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.405E-04 | 4.602E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.405E-04 | 4.602E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.405E-04 | 4.602E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.405E-04 | 4.602E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004222; metalloendopeptidase activity | 1.449E-04 | 4.731E-03 | MMP1, MMP12, MMP13, MMP2, MMP3, MMP9 |
MF | GO:0005488; binding | GO:0001085; RNA polymerase II transcription factor binding | 1.520E-04 | 4.931E-03 | AHR, AR, ESR1, GSK3B, PPARA, TP53 |
BP | GO:0009987; cellular process | GO:0001959; regulation of cytokine-mediated signaling pathway | 1.590E-04 | 5.151E-03 | AXL, HIF1A, MMP12, NR1H4, PPARG, PTPN1, SYK |
BP | GO:0051179; localization | GO:0051051; negative regulation of transport | 1.659E-04 | 5.328E-03 | ADRA2A, ADRA2C, AKT1, APP, DRD4, FFAR4, GSK3B, MMP9, NFKB1, NR1H4, PTGS2, TLR2 |
BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 1.735E-04 | 5.556E-03 | ADRA2A, CAMK2B, DRD4, FFAR1, HTT, NPSR1, PLA2G1B, PTGS2 |
BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 1.792E-04 | 5.730E-03 | AKR1B1, AKT1, MMP2, MMP9, PTGS2 |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 1.914E-04 | 6.048E-03 | APP, CA2, CA7, DRD4, MAPK1, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.963E-04 | 6.177E-03 | AKT1, AURKA, AURKB, MAPK1 |
BP | GO:0008152; metabolic process | GO:0050731; positive regulation of peptidyl-tyrosine phosphorylation | 1.976E-04 | 6.199E-03 | ADRA2A, ADRA2C, FLT3, PTPN1, SRC, SYK, TP53 |
CC | GO:0016020; membrane | GO:0045121; membrane raft | 1.982E-04 | 6.209E-03 | APP, BACE1, KDR, MAPK1, NPC1, PTGS2, SRC, STAT6, TLR2 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.987E-04 | 6.217E-03 | CAMK2B, CDK1, CFTR, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HSD17B2, NOX4, PTGS1, PTGS2, RAB9A |
BP | GO:0008152; metabolic process | GO:0046209; nitric oxide metabolic process | 2.022E-04 | 6.299E-03 | AKT1, CYP1B1, TLR2 |
BP | GO:0050896; response to stimulus | GO:0033189; response to vitamin A | 2.022E-04 | 6.299E-03 | CYP1A1, PPARD, PPARG |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 2.196E-04 | 6.772E-03 | AKT1, AURKA, AURKB, CSNK2A1, L3MBTL1, NUAK1, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 2.356E-04 | 7.194E-03 | AKT1, HIF1A, KDR, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 2.356E-04 | 7.194E-03 | AKR1B1, AKR1B10, ALDH1A1, XDH |
BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 2.466E-04 | 7.458E-03 | ADRA2A, AKT1, CFTR, DRD4, FFAR1, HTT, NPSR1, PLA2G1B |
BP | GO:0009987; cellular process | GO:0045787; positive regulation of cell cycle | 2.519E-04 | 7.596E-03 | AKT1, APP, AURKA, AURKB, CDK1, CDK9, CYP1A1, SRC, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 2.572E-04 | 7.724E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008152; metabolic process | GO:0016125; sterol metabolic process | 2.597E-04 | 7.789E-03 | APP, CFTR, CYP19A1, CYP1B1, NPC1, PPARD |
BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 2.798E-04 | 8.200E-03 | NMUR2, PLA2G1B |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.798E-04 | 8.200E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.798E-04 | 8.200E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.798E-04 | 8.200E-03 | TNKS, TNKS2 |
BP | GO:0032501; multicellular organismal process | GO:0032640; tumor necrosis factor production | 2.798E-04 | 8.200E-03 | APP, TLR2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.798E-04 | 8.200E-03 | CYP1A1, CYP1A2 |
BP | Unclassified; | GO:0042993; positive regulation of transcription factor import into nucleus | 2.802E-04 | 8.200E-03 | APP, PIK3R1, PTGS2, TLR2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.798E-04 | 8.200E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0005497; androgen binding | 2.798E-04 | 8.200E-03 | ALDH1A1, AR |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 2.954E-04 | 8.577E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HTT, MAPT, MMP9, NOX4, PPARG, PTGS2, SRC, TP53, XDH |
BP | Unclassified; | GO:1905953; negative regulation of lipid localization | 3.046E-04 | 8.820E-03 | AKT1, NFKB1, PPARA, PPARG |
BP | GO:0032502; developmental process | GO:0048638; regulation of developmental growth | 3.078E-04 | 8.888E-03 | AKT1, APP, AR, CDK1, MAPT, PIM1, PPARD, PTK2, TNKS2 |
BP | GO:0008283; cell proliferation | GO:0048145; regulation of fibroblast proliferation | 3.198E-04 | 9.162E-03 | CDK6, ESR1, PLA2G1B, PPARG, TP53 |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.442E-21 | 3.489E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 8.714E-18 | 1.116E-14 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, GLO1, KDM2A, KDM7A, L3MBTL1, MMP1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H4, NR1I2, PARP1, PHF8, PPARA, PPARD, PPARG, PTPN1, TNKS, TP53 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.197E-16 | 1.170E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 3.710E-14 | 1.443E-11 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.707E-13 | 5.235E-11 | ADRA2A, AURKB, CA2, CA7, CD38, CDK6, CFTR, HIF1A, HTT, KDR, MAPK1, NEK2, NPC1, NPSR1, NR1H4, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2, TRPA1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 2.397E-13 | 6.778E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, PTGS1, PTGS2, SRC |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.191E-13 | 8.686E-11 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2A6, CYP2C19, CYP2C8, CYP2C9, CYP3A4, KDM7A, PHF8, XDH |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 8.824E-21 | 1.694E-18 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.975E-12 | 1.896E-10 | GSK3B; FLT3; MMP1; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; CDK6; AKT1; MAPK1; PPARG; MET; TP53; PPARD |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 6.311E-12 | 4.039E-10 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET; TLR2 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 2.914E-10 | 1.119E-08 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 2.195E-10 | 1.054E-08 | CYP2C9; APP; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; ALOX12; CYP2C19; PTGS2; PTGS1 |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.313E-09 | 3.601E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.777E-10 | 2.169E-08 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 3.766E-08 | 5.165E-07 | PLA2G1B; MAOA; ALOX15; AKR1B1; ALOX12; PYGL; PTGS2; CYP2C19; CYP3A4; CYP19A1; HSD17B10; PTGS1; HSD17B1; ALOX5; HSD17B2; CD38; XDH; GAA; TYR; CYP2C9; CYP2C8; CYP2A6; PKM; AKR1B10; CYP1A2; ALDH1A1; CYP1A1 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 3.763E-09 | 9.032E-08 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19; PTGS2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.451E-08 | 2.786E-07 | PKM; FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 2.590E-08 | 4.144E-07 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 9.136E-09 | 1.949E-07 | MMP1; DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.614E-08 | 7.937E-07 | GSK3B; SYK; PIK3R1; PTK2; NFKB1; IGF1R; CDK6; KDR; AKT1; MAPK1; PKN1; TP53; MET; TLR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.946E-08 | 6.331E-07 | CDK6; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1; TLR2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 3.367E-08 | 4.973E-07 | CDK9; FLT3; MMP3; PPARG; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 1.840E-08 | 3.211E-07 | FABP2; FABP3; FABP4; FABP5; MMP1; PPARG; PPARA; PPARD |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.390E-07 | 1.405E-06 | GSK3B; AR; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 9.835E-08 | 1.111E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1; PPARD |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 2.478E-07 | 2.163E-06 | CAMK2B; CDK6; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.588E-07 | 1.524E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTGS2; PTK2 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 3.178E-07 | 2.550E-06 | GSK3B; CDK6; CSNK2A1; AKT1; RAB9A; PIK3R1; TP53; NFKB1; TLR2 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 3.188E-07 | 2.550E-06 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; ESR2 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.161E-06 | 8.253E-06 | POLB; CDK6; PKM; SYK; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.112E-07 | 1.187E-06 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 2.478E-07 | 2.163E-06 | CYP2C9; CYP2C8; CYP2A6; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 4.580E-07 | 3.382E-06 | CDK6; AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.226E-06 | 8.404E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.757E-07 | 2.885E-06 | CYP2C9; CYP2C8; CYP2A6; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.842E-06 | 1.145E-05 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.704E-06 | 1.128E-05 | CDK6; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 8.460E-06 | 4.171E-05 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; TP53; NFKB1 |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 8.460E-06 | 4.171E-05 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 5.720E-06 | 3.138E-05 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 8.323E-06 | 4.171E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PPARA; NFKB1 |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.909E-06 | 1.145E-05 | ALK; CDK6; AKT1; MAPK1; PIK3R1; TP53 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 8.840E-06 | 4.171E-05 | MMP3; AKT1; MAPK1; PIK3R1; PTGS2; MMP9; NFKB1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.909E-06 | 1.145E-05 | FABP4; AKT1; PIK3R1; PTGS2; TSHR; PTGS1 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 5.058E-06 | 2.856E-05 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 3.029E-05 | 1.244E-04 | ABCC1; CDK6; PIM1; CYP1B1; MAPK1; PTGS2; TP53; MMP9; MET; NFKB1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.564E-05 | 6.825E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 9.123E-06 | 4.171E-05 | CDK6; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 9.123E-06 | 4.171E-05 | GSK3B; SYK; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.641E-05 | 1.456E-04 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 4.231E-05 | 1.625E-04 | PARP1; LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 3.045E-05 | 1.244E-04 | GSK3B; AKT1; MAPK1; PIK3R1; PPARA; TP53; NFKB1 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.655E-05 | 2.114E-04 | CAMK2B; AKT1; MAPK1; PIK3R1; PPARA; CFTR; NFKB1; TSHR |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 5.835E-05 | 2.114E-04 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 3.894E-05 | 1.526E-04 | AKT1; PPARG; PIK3R1; TP53; NFKB1; IGF1R |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 9.875E-06 | 4.409E-05 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 9.123E-06 | 4.171E-05 | CYP2C9; CYP2A6; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.413E-04 | 4.697E-04 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 1.384E-04 | 4.697E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 1.661E-04 | 5.315E-04 | SYK; SRC; AKT1; MAPK1; PIK3R1; PTGS1 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.906E-04 | 5.904E-04 | CAMK2B; SYK; SRC; AKT1; MAPK1; NFKB1; TLR2 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 1.737E-04 | 5.466E-04 | CAMK2B; AR; CDK1; MAPK1; AURKA; IGF1R |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 1.517E-04 | 4.938E-04 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 2.549E-04 | 7.768E-04 | SYK; AKT1; MAPK1; PPARG; PIK3R1; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 5.333E-04 | 1.506E-03 | SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 3.366E-04 | 1.010E-03 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.439E-05 | 1.041E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 4.993E-04 | 1.431E-03 | CAMK2B; TRPA1; SRC; ALOX12; PIK3R1 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 6.641E-04 | 1.771E-03 | CAMK2B; SRC; CD38; MAPK1; PIK3R1; PTGS2 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 4.993E-04 | 1.431E-03 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 7.785E-05 | 2.768E-04 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 5.732E-04 | 1.595E-03 | CAMK2B; PKM; AKT1; PYGL; PPARA |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 5.758E-05 | 2.114E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 9.146E-04 | 2.308E-03 | BACE1; APP; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 6.550E-04 | 1.771E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 8.797E-04 | 2.252E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 3.923E-04 | 1.159E-03 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 6.550E-04 | 1.771E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 1.104E-04 | 3.856E-04 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 7.142E-04 | 1.853E-03 | AKT1; MAPK1; PIK3R1; NFKB1; TLR2 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 2.612E-03 | 5.832E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 2.612E-03 | 5.832E-03 | CAMK2B; GSK3B; CSNK2A1; TP53; PPARD |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 2.775E-03 | 6.124E-03 | SYK; CXCR1; AKT1; MAPK1; PIK3R1 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 1.443E-03 | 3.379E-03 | AKT1; PPARG; PIK3R1; CFTR; IGF1R |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.718E-03 | 3.974E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 3.402E-03 | 7.258E-03 | GSK3B; AKT1; PIK3R1; PPARA; NFKB1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 4.126E-03 | 8.338E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.643E-03 | 1.453E-02 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 6.330E-03 | 1.215E-02 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 7.957E-03 | 1.492E-02 | CSNK2A1; CDK1; TP53; NFKB1; TLR2 |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 5.210E-03 | 1.010E-02 | AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 3.196E-03 | 6.895E-03 | CAMK2B; SRC; MMP2; MAPK1 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 2.960E-02 | 4.510E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.720E-02 | 2.897E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 3.456E-03 | 7.292E-03 | SYK; AKT1; MAPK1; PIK3R1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.794E-02 | 4.326E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 3.221E-02 | 4.831E-02 | CXCR1; THPO; FLT3; KDR; MET |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 4.479E-03 | 8.867E-03 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 8.001E-03 | 1.492E-02 | MMP2; PIK3R1; MMP9; PTK2 |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 4.479E-03 | 8.867E-03 | PIK3R1; NFKB1; PTK2; TLR2 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 4.641E-03 | 9.092E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 1.204E-02 | 2.064E-02 | AKT1; MAPK1; PIK3R1; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 9.489E-03 | 1.703E-02 | GSK3B; CDK6; CDK1; TP53 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 3.873E-03 | 7.996E-03 | CA2; PLA2G1B; CD38; CFTR |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 1.030E-02 | 1.814E-02 | GSK3B; MAPK1; MET; PTK2 |
hsa05140 | Leishmaniasis_Homo sapiens_hsa05140 | 1.427E-03 | 3.379E-03 | MAPK1; PTGS2; NFKB1; TLR2 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.823E-03 | 4.166E-03 | SRC; PIK3R1; MET; PTK2 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 1.095E-03 | 2.628E-03 | SYK; AKT1; MAPK1; PIK3R1 |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 6.832E-04 | 1.797E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
hsa05323 | Rheumatoid arthritis_Homo sapiens_hsa05323 | 2.220E-02 | 3.552E-02 | MMP1; MMP3; TLR2 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 2.093E-02 | 3.378E-02 | THPO; FLT3; CD38 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 1.095E-03 | 2.628E-03 | CXCR1; SRC; MET; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 2.093E-02 | 3.378E-02 | SRC; CDK1; MAPK1 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.971E-02 | 3.262E-02 | MAPK1; PKN1; NFKB1 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 1.322E-02 | 2.246E-02 | CAMK2B; CA2; CFTR |
hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 1.138E-02 | 1.968E-02 | AKT1; PPARA; NFKB1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 8.915E-03 | 1.646E-02 | AKT1; PIK3R1; IGF1R |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 1.094E-02 | 1.910E-02 | CDK6; CDK1; TP53 |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 9.301E-03 | 1.685E-02 | SRC; MAPK1; NFKB1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 9.301E-03 | 1.685E-02 | STAT6; NFKB1; TLR2 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.419E-04 | 4.697E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 3.997E-03 | 8.164E-03 | PKM; MAPK1; PIK3R1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 3.120E-03 | 6.808E-03 | ABCC1; CFTR; ABCG2 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.542E-03 | 7.392E-03 | CYP2A6; CYP3A4; XDH |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 2.770E-02 | 4.324E-02 | MAPK1; PIK3R1 |
hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 3.040E-02 | 4.595E-02 | FABP2; PLA2G1B |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.904E-02 | 4.460E-02 | PKM; GLO1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 9.257E-04 | 2.308E-03 | MAPK1; PPARG; TP53 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.024E-03 | 2.519E-03 | AKR1B10; GAA; AKR1B1 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 2.263E-02 | 3.591E-02 | MAOA; TYR |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.911E-02 | 3.191E-02 | AKR1B10; AKR1B1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 2.026E-02 | 3.324E-02 | POLB; PARP1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 2.386E-02 | 3.755E-02 | AKR1B10; AKR1B1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 1.013E-02 | 1.802E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.847E-06 | 1.657E-05 | CYP2A6; CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5; RAB9A |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; MMP12; MMP12; ALOX5 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
NA: NA | Menopausal disorder | NA | ESR1 |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | TLR2; PARP1; TYR; KDR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; ALOX5 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; TLR2; CSNK2A1; SYK; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; SRC; IGF1R; CD38; AURKA; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; PARP1; PTK2; TP53; ESR1; ESR1; CA1; KDR; APP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; CD38; AURKB; TP53 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
NA: NA | Male hypogonadism | NA | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2; SYK; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; PTGS2; PTGS2; ALOX5; MMP1 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; SYK; SYK; MMP12; PTGS2; ALOX5; ALOX5; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | NR1I2; MMP12; ALOX5; PPARD |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | PPARD |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; ALOX5 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; TLR2; FLT3; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; ESR1; ESR1; KDR; KDR; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | PPARG |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1; ESR1; APP |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS1; PTGS2; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC |
NA: NA | Joint and muscular pain | NA | PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARG; PPARD |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; PTPN1; PTPN1; PTGS2; NFKB1; PPARG; PPARG; PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; PTGS1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2; PPARG |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; ADRA2C; PPARG; PPARD; PPARD |
K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARG; PPARD |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; MMP13; SYK; MMP12; PTGS1; PTGS2; ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | PTGS1; MMP9 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
NA: NA | Dyslipidemia | NA | PPARD |
E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | FFAR1; AKR1B1; PTPN1; GSK3B; PPARG |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
NA: NA | HIV infections | NA | AHR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Dietary shortage | E40-E46 | PTGS1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | PPARG |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; PTK2; TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ESRRA; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5; TYR; MMP1 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS1; PTGS2; PTGS2; PTGS2 |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; TLR2; PKM; SYK; FLT3; CA9; MMP2; SRC; IGF1R; AURKB; AURKA; HIF1A; MAPK1; MMP9; PTK2; TP53; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C; MMP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; PTGS1; ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; TLR2; FLT3; MMP2; PTGS2; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD; ESR1 |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
H00-H59: Diseases of the eye and adnexa | Ocular inflammation | H16.229 | PPARG |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | MMP13; MMP3; MMP2; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; ALOX5 |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; ADRA2C; PPARG; PPARG; APP |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; SYK; ALOX5 |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PPARG |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
NA: NA | Geographic retinal atrophy | NA | APP |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
NA: NA | GIST | NA | FLT3 |
NA: NA | Colour dead tissues | NA | PTPN1 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R; CD38 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ESR1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2; PTGS1; ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
NA: NA | Miosis during ocular surgery | NA | PTGS1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; PPARD |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS1; PTGS2; PPARG |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ACHE; PTGS1; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; CDK1; ADRA2C; ADRA2A; TRPA1; ESR1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Postoperative inflammation | T81 | PTGS1 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; AURKA |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; AURKA; TP53; TP53 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | SYK; ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1 |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; PTGS1; IGF1R; MMP9; TP53; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |